James C Tsai1, Cameron C Johnson, Mary S Dietrich. 1. Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA. jct2002@columbia.edu
Abstract
PURPOSE: To compare the surgical outcome of Baerveldt and Ahmed shunt implants in the treatment of refractory glaucoma. DESIGN: Retrospective, nonrandomized, comparative trial. METHODS AND PARTICIPANTS: Medical records of 118 consecutive patients who underwent glaucoma shunt implantation (70 Baerveldt, 48 Ahmed) by a single surgeon were reviewed. MAIN OUTCOME MEASURES: The primary outcome measure was surgical success (6 mmHg <or= intraocular pressure [IOP] <or= 21 mmHg without additional glaucoma surgery or devastating complication) at 12 months after surgery. Secondary outcome measures included mean IOP and number of medications used at the following postoperative visits: day 1, 1 week, 1 month, 3 months, 6 months, and every 6 months thereafter. Additional outcome measures evaluated include visual acuities, prevalence and timing of postoperative choroidal detachment, and clinical bleb encapsulation. RESULTS: Survival curve analysis showed success rates of 82.9% of the Ahmed group and 72.9% of the Baerveldt group at 12 months after surgery (P = 0.257). Patients in the Ahmed group exhibited lower IOPs at 1 day (P < 0.001) and 1 week (P < 0.001) after surgery and were taking fewer glaucoma medications at 1 week (P < 0.001) and 1 month (P < 0.001) after surgery. A higher proportion of Ahmed patients experienced clinical bleb encapsulation than did the Baerveldt patients (60.4% vs. 27.1%; P < 0.001). Moreover, the first observation of postoperative bleb encapsulation was sooner after surgery for the Ahmed patients (50.0 +/- 43.8 days) than for the Baerveldt patients (69.8 +/- 22.6 days; P = 0.001). CONCLUSIONS: The Ahmed shunt implant exhibited better control of IOP in the early postoperative period (1 day and 1 week) with patients requiring fewer glaucoma medications at 1 week and 1 month after surgery. There was both a higher prevalence and earlier onset of bleb encapsulation observed with the Ahmed shunt implant.
PURPOSE: To compare the surgical outcome of Baerveldt and Ahmed shunt implants in the treatment of refractory glaucoma. DESIGN: Retrospective, nonrandomized, comparative trial. METHODS AND PARTICIPANTS: Medical records of 118 consecutive patients who underwent glaucoma shunt implantation (70 Baerveldt, 48 Ahmed) by a single surgeon were reviewed. MAIN OUTCOME MEASURES: The primary outcome measure was surgical success (6 mmHg <or= intraocular pressure [IOP] <or= 21 mmHg without additional glaucoma surgery or devastating complication) at 12 months after surgery. Secondary outcome measures included mean IOP and number of medications used at the following postoperative visits: day 1, 1 week, 1 month, 3 months, 6 months, and every 6 months thereafter. Additional outcome measures evaluated include visual acuities, prevalence and timing of postoperative choroidal detachment, and clinical bleb encapsulation. RESULTS: Survival curve analysis showed success rates of 82.9% of the Ahmed group and 72.9% of the Baerveldt group at 12 months after surgery (P = 0.257). Patients in the Ahmed group exhibited lower IOPs at 1 day (P < 0.001) and 1 week (P < 0.001) after surgery and were taking fewer glaucoma medications at 1 week (P < 0.001) and 1 month (P < 0.001) after surgery. A higher proportion of Ahmed patients experienced clinical bleb encapsulation than did the Baerveldtpatients (60.4% vs. 27.1%; P < 0.001). Moreover, the first observation of postoperative bleb encapsulation was sooner after surgery for the Ahmed patients (50.0 +/- 43.8 days) than for the Baerveldtpatients (69.8 +/- 22.6 days; P = 0.001). CONCLUSIONS: The Ahmed shunt implant exhibited better control of IOP in the early postoperative period (1 day and 1 week) with patients requiring fewer glaucoma medications at 1 week and 1 month after surgery. There was both a higher prevalence and earlier onset of bleb encapsulation observed with the Ahmed shunt implant.
Authors: Keith Barton; William J Feuer; Donald L Budenz; Joyce Schiffman; Vital P Costa; David G Godfrey; Yvonne M Buys Journal: Ophthalmology Date: 2014-04-24 Impact factor: 12.079
Authors: Donald L Budenz; Keith Barton; Steven J Gedde; William J Feuer; Joyce Schiffman; Vital P Costa; David G Godfrey; Yvonne M Buys Journal: Ophthalmology Date: 2014-10-17 Impact factor: 12.079
Authors: Manuel Diaz-Llopis; David Salom; Salvador García-Delpech; Patricia Udaondo; Jose Maria Millan; J Fernando Arevalo Journal: Clin Ophthalmol Date: 2010-05-06
Authors: Juan Carlos Mesa-Gutiérrez; Juan Lillo-Sopena; Anna Monés-Llivina; Silvia Sanz-Moreno; Jorge Arruga-Ginebreda Journal: Clin Ophthalmol Date: 2010-04-26
Authors: Oscar Albis-Donado; Félix Gil-Carrasco; Rafael Romero-Quijada; Ravi Thomas Journal: Indian J Ophthalmol Date: 2010 Sep-Oct Impact factor: 1.848
Authors: Donald L Budenz; William J Feuer; Keith Barton; Joyce Schiffman; Vital P Costa; David G Godfrey; Yvonne M Buys Journal: Am J Ophthalmol Date: 2015-11-18 Impact factor: 5.258